Accessible & acceptable birth control solutions for all women—no hormones, no copper, no compromises.

Redefining Contraceptive Care

WHAT WE’RE BUILDING

A new female birth control solution designed to be highly effective, long-acting and side-effect-free.

THE STANDARD OF BIRTH CONTROL TODAY

The birth control pill was developed in the 1950s.

The birth control pill was FDA approved in 1960. All hormonal methods use the same mechanisms of action as “the pill,” and they can cause the same side effects.

The first copper IUD was FDA approved in 1984.

The first hormonal IUD was approved in 2000.

Half of pregnancies are unplanned.

30% of all maternal deaths result from unplanned pregnancies.

In 2010, the US government spent $21 billion on the births, abortions, and miscarriages that resulted from unplanned pregnancies.

Hormonal and copper birth control options cause side effects.

All highly effective and reversible methods use hormones or copper. Hormones and copper can cause cause unwanted or adverse side effects.

50% of women stop using their birth control because they are unhappy with or cannot tolerate the side effects.

HOW WE’RE DIFFERENT

Bridging The Gap Between IUDs and Barrier Methods

Existing birth control methods do not meet the needs of 50% of women today. We’re pioneering a new class of long-acting barrier contraception.

OUR SOLUTION

A Long-Acting Barrier Device

A birth control device for women that is highly effective, long lasting, hormone-free, and copper-free

OUR MISSION

Innovating For All

To offer more acceptable and affordable birth control options for all women to help them gain full control over their family planning

Supported By

Company Updates

  • $2.23M NIH SBIR Phase II Grant

    July 2025

    Venova Technologies awarded a $2.23M SBIR Phase II grant to accelerate the preclinical development of the company’s cervical barrier device.

  • HealthTech Capital Readiness Program

    April 2025

    Our CEO and COO/CFO participated in the Science Center’s competitive week-long due diligence deep dive for healthtech founders.

  • IWD: Women Leading The Future Keynote

    March 2025

    Our CEO gave a keynote and participated on a panel at LabCentral & J&J’s International Women’s Day celebration.

  • $380K NIH SBIR Phase I Grant

    September 2024

    Venova Technologies received their second SBIR/STTR Phase I grant, marking their fourth awarded project from the NIH.

  • WHIS Innovation Showcase Award

    September 2024

    Our CEO pitched and won the prestigious WHIS Innovation Showcase award for the Therapeutic, Diagnostic, and Medical Device category.

  • Reproductive Health Innovation Summit

    February 2024

    Our CEO presented on panel, “A New Age for Contraception? Opportunities to Improve the Benchmark Beyond Innovation” with the NIH, Gates Foundation, and Foreground Capital.

  • National Contraception Meeting

    November 2023

    Our CEO and Chief Medical Advisor presented updates on ongoing NIH-funded projects at the annual contraceptive meeting.

  • First Place Life Sciences Eddie Award

    November 2023

    Venova Technologies was awarded the first place 2023 Life Sciences Eddie Award (formerly New England Innovation Award).

  • LabCentral Ignite Golden Ticket Award

    September 2023

    Venova Technologies was awarded a LabCentral Ignite Golden Ticket, providing mentorship, a cash prize, and lab space to underrepresented founders.

  • NIH/NICHD X01 Service Contract

    February 2023

    Venova Technologies received their second NICHD X01 Biological Testing Facility Service Request to perform in vitro barrier efficiency testing with human sperm.

  • $300K NIH STTR Phase I Grant

    September 2022

    Venova Technologies received their first SBIR/STTR Phase I grant, focused on completing their ex vivo study and developing their device for in vitro efficacy testing.

  • NIH/NICHD X01 Service Contract

    June 2022

    Venova Technologies received a NIH/NICHD X01 Biological Testing Facility Service Request to perform their first preclinical study in baboons.

Latest Updates

INTERDISCIPLINARY APPROACH

Guided by Industry Knowledge and Medical Research

MISSION-DRIVEN & IMPACT-ORIENTED

An Underserved Market with High Upside Potential

Offering a highly effective, long-acting, and side-effect-free birth control option will give hundreds of millions of women and girls more autonomy over their health, leading to healthier families and more prosperous societies.